
Photo taken from ESMO/LinkedIn
Jun 27, 2024, 09:10
The promise of immuno-oncology in the neoadjuvant setting – ESMO
The European Society for Medical Oncology (ESMO) shared on LinkedIn:
“The promise of immuno-oncology in the neoadjuvant setting.
Recent studies highlight novel pre-operative therapeutic options that are showing promise.
While there are still challenges to address, early clinical trials in the neoadjuvant setting could pave the way for practice-changing strategies to help a larger number of people with cancer.
To learn more about this topic, read the ESMO Daily Reporter new column by Elena Garralda Cabanas.”
Source: ESMO/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 11:36
Feb 21, 2025, 11:29
Feb 21, 2025, 10:45
Feb 21, 2025, 10:07